Mark Stampehl, MD is a cardiologist with a career focus on building innovative systems of care for patients with heart failure across multiple practice environments through process engineering and leveraging technologies. As LifeWave Biomedical Chief Medical Officer, he leads clinical strategy, evidence generation, medical affairs, and clinical operations in close coordination with the executive team. Patient centricity, safety, efficacy, and value are his core interests.

Before joining LifeWave, Mark most recently helped lead heart failure and cardiovascular medical affairs as Executive Medical Director for Novartis Pharmaceuticals Corporation. In this role, he collaborated with Anumana in concept development and feasibility clinical trials of artificial intelligence software to predict low left ventricular ejection fraction via 12-lead ECG as well as an EHR-integrated heart failure medical optimization tool. Other leadership contributions included a post on the steering committee for the American Heart Association’s IMPLEMENT-HF implementation science program and the steering committee of the National Hypertension Control Roundtable.

Building care delivery systems and remote monitoring technology has spanned the arc of his career. Beginning with use of telemedicine for subspecialty care of soldiers and civilians while serving in the U.S. Army to expanding a hub-and-spoke model for remote heart failure care across rural Illinois served the quality and access needs of his patients. Remote monitoring via tele-scale technology, subcutaneous sensors, and pulmonary artery pressure monitors provided inputs to his team to manage highly complex patients with among the lowest rates of hospitalization in the region.

Mark also served as an executive leader of a 77-cardiologist single specialty practice within a large integrated health system, Hospital Sisters Health System, as well as chairperson of the HSHS Accountable Care Organization quality program. He contributed to medical device and pharmaceutical innovation through several years of senior advisory to the Medtronic Heart Failure Management Medical Advisory Team, Novartis Pharmaceuticals health economics and outcomes group as well as medical affairs group, and steering committee advisory to CardioKinetix in the development of an intraventricular remodeling device.

He took graduate molecular biology training from Washington University and earned his medical degree at Saint Louis University School of Medicine. Internal medicine residency, cardiovascular diseases fellowship, and Bugher molecular cardiology post-doctoral fellowship training were all accomplished at Baylor College of Medicine. He also served 14 years in the U.S. Army and Army National Guard as a field surgeon and brigade surgeon. He is a Fellow of the Heart Failure Society of America.